Amgen Set To Face Off With Hospira In Biosimilar IP Trial
By Matt Chiappardi ( September 8, 2017, 7:16 PM EDT) -- Pharmaceutical companies Amgen Inc. and Hospira Inc. are set to square off later this month in a patent infringement trial centering on Hospira's efforts to produce a biosimilar version of Amgen's anti-anemia drug Epogen after the sides completed their final pre-trial conference in Delaware on Friday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.